Clinical outcomes of allergen immunotherapy in children in Latin America: Treatment with polymerized allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae.

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal Pub Date : 2025-08-07 eCollection Date: 2025-08-01 DOI:10.1016/j.waojou.2025.101094

Ricardo Cardona-Villa, Sandra Del Pozo, Susana Uribe-García, Víctor Daniel Calvo-Betancur, Enrique Fernández-Caldas, Jorge Sánchez

{"title":"Clinical outcomes of allergen immunotherapy in children in Latin America: Treatment with polymerized allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae.","authors":"Ricardo Cardona-Villa, Sandra Del Pozo, Susana Uribe-García, Víctor Daniel Calvo-Betancur, Enrique Fernández-Caldas, Jorge Sánchez","doi":"10.1016/j.waojou.2025.101094","DOIUrl":null,"url":null,"abstract":"Background: Subcutaneous allergen immunotherapy (SCIT) is recognized as an effective and safe treatment for children and adults suffering from allergic respiratory diseases driven by house dust mites (HDM) in tropical regions.Objectives: To assess the clinical effectiveness and safety of SCIT using glutaraldehyde-polymerized allergen extracts of Dermatophagoides pteronyssinus and D. farinae in Colombian pediatric patients.Methods: A retrospective, observational study including 49 children diagnosed with HDM-induced allergic rhinitis, with or without asthma, who were treated with SCIT for 1 year. Primary endpoints were measured using the Combined Symptom and Medication Score (CSMS). Secondary outcomes were asthma medication use and Asthma Control Test (ACT) scores.Results: Significant improvement in CSMS (median reduction: -0.8; p = 0.015) and ACT scores (median increase: -1.3; p = 0.015) were observed within 3 months; 76% of patients had at least a 20% of reduction of the CSMS compared to baseline after 6 months with immunotherapy (IT). Medication use for asthma decreased significantly after 1 year (p = 0.035).Conclusion: SCIT using polymerized HDM extracts demonstrated to be effective and safe in allergic pediatric populations.","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"101094"},"PeriodicalIF":4.3000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355523/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Allergy Organization Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.waojou.2025.101094","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Subcutaneous allergen immunotherapy (SCIT) is recognized as an effective and safe treatment for children and adults suffering from allergic respiratory diseases driven by house dust mites (HDM) in tropical regions.

Objectives: To assess the clinical effectiveness and safety of SCIT using glutaraldehyde-polymerized allergen extracts of Dermatophagoides pteronyssinus and D. farinae in Colombian pediatric patients.

Methods: A retrospective, observational study including 49 children diagnosed with HDM-induced allergic rhinitis, with or without asthma, who were treated with SCIT for 1 year. Primary endpoints were measured using the Combined Symptom and Medication Score (CSMS). Secondary outcomes were asthma medication use and Asthma Control Test (ACT) scores.

Results: Significant improvement in CSMS (median reduction: -0.8; p = 0.015) and ACT scores (median increase: -1.3; p = 0.015) were observed within 3 months; 76% of patients had at least a 20% of reduction of the CSMS compared to baseline after 6 months with immunotherapy (IT). Medication use for asthma decreased significantly after 1 year (p = 0.035).

Conclusion: SCIT using polymerized HDM extracts demonstrated to be effective and safe in allergic pediatric populations.

查看原文本刊更多论文

拉丁美洲儿童过敏原免疫治疗的临床结果：用翼状棘球蚴和粉状棘球蚴的聚合过敏原提取物治疗。

背景：皮下过敏原免疫治疗（SCIT）被认为是一种有效和安全的治疗方法，用于治疗热带地区由屋尘螨（HDM）引起的儿童和成人过敏性呼吸道疾病。目的：评价哥伦比亚儿童患者应用蝶翼棘球蚴和粉棘球蚴戊二醛聚合变应原提取物进行SCIT的临床疗效和安全性。方法：一项回顾性观察性研究，包括49名诊断为hdm诱发的变应性鼻炎，伴或不伴哮喘的儿童，他们接受了1年的SCIT治疗。主要终点采用症状和药物联合评分（CSMS）进行测量。次要结局是哮喘药物使用和哮喘控制测试（ACT）得分。结果：在3个月内，CSMS（中位数降低：-0.8,p = 0.015）和ACT评分（中位数增加：-1.3,p = 0.015）均有显著改善；在接受免疫治疗（IT） 6个月后，76%的患者的cms与基线相比至少减少了20%。1年后哮喘用药明显减少（p = 0.035）。结论：SCIT使用聚合HDM提取物证明是有效和安全的过敏性儿童人群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Allergy Organization Journal Immunology and Microbiology-Immunology

CiteScore

9.10

自引率

5.90%

发文量

审稿时长

9 weeks

期刊介绍： The official pubication of the World Allergy Organization, the World Allergy Organization Journal (WAOjournal) publishes original mechanistic, translational, and clinical research on the topics of allergy, asthma, anaphylaxis, and clincial immunology, as well as reviews, guidelines, and position papers that contribute to the improvement of patient care. WAOjournal publishes research on the growth of allergy prevalence within the scope of single countries, country comparisons, and practical global issues and regulations, or threats to the allergy specialty. The Journal invites the submissions of all authors interested in publishing on current global problems in allergy, asthma, anaphylaxis, and immunology. Of particular interest are the immunological consequences of climate change and the subsequent systematic transformations in food habits and their consequences for the allergy/immunology discipline.